Glaukos Corporation (NYSE:GKOS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Glaukos Corporation (NYSE:GKOS) have earned an average recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $133.6923.

Several research analysts have weighed in on GKOS shares. Wells Fargo & Company lifted their price objective on shares of Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a research note on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Piper Sandler reiterated an “overweight” rating and issued a $165.00 price objective on shares of Glaukos in a research note on Wednesday, January 14th. Finally, William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research note on Friday, January 30th.

Glaukos Stock Performance

Shares of GKOS stock opened at $124.45 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of -38.17 and a beta of 0.78. The company has a 50-day simple moving average of $111.90 and a 200 day simple moving average of $105.43. Glaukos has a 52 week low of $73.16 and a 52 week high of $130.23.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.40) EPS. On average, sell-side analysts predict that Glaukos will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 2,511 shares of Glaukos stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer owned 41,967 shares in the company, valued at $4,467,806.82. The trade was a 5.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares of the company’s stock, valued at $4,782,611.79. This trade represents a 28.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 49,657 shares of company stock worth $6,067,269 over the last quarter. Company insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. raised its position in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares in the last quarter. First Horizon Corp raised its position in shares of Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Glaukos in the 4th quarter valued at approximately $28,000. Larson Financial Group LLC raised its position in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares in the last quarter. Finally, REAP Financial Group LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at approximately $40,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.